Shareholders give thumbs-up to disputed Transkaryotic takeover

A narrow majority of shareholders of Transkaryotic Therapies has approved the biotechnology firm's $1.6 billion sale to a British drug company. The takeover by Shire Pharmaceuticals had been opposed by Transkaryotics' former CEO, who quit in protest. Key investors had also argued the price that Shire is paying is too low. Dissident shareholders, including investor Carl Icahn, are expected to continue fighting the deal in court.

- read this story from the Boston Herald for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.